Skip to main content
. 2019 Apr 2;13:97. doi: 10.3389/fncel.2019.00097

Figure 3.

Figure 3

No change in oligo precursors and mature oligos from PLX5622 treatment. Representative images of the SVZ from 14d of PLX5622 treatment (A), with the dashed line separating the SVZ from the lateral ventricle. DAPI in blue, neural/glial antigen 2 (NG2) in green, and CC1 in red. Quantification of mature oligos in (B, p = 0.6101) and oligo precursors in (C, p = 0.2670). n = 6 for all groups, two sections per n plotted as per SVZ wall.